SAILIFE1,591.50

Sai Life Sciences Ltd.

· Pharma & Health
₹ CrorePeersSYNGENEDIVISLABPPLPHARMANHNEULANDLABNATCOPHARMLALPATHLABCOHANCEMcap ₹33,705 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt128.695.195.1
Net Debt37.5-33.8-33.8
Total Debt/Equity0.060.040.04
Net Debt/Equity0.02-0.01-0.01
Total Debt/EBITDA0.320.150.15
Net Debt/EBITDA0.09-0.05-0.05
Interest Coverage (EBIT/Interest)3.5111.8311.83
Total Debt/Total Capital %5.703.693.69
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.